Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05311865
Other study ID # ANRS0066s
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 4, 2021
Est. completion date February 26, 2022

Study information

Verified date April 2022
Source ANRS, Emerging Infectious Diseases
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The ITOC study is a cluster randomised, controlled, multicentre trial in Paris region, France. The intervention is an 8-hour indoor clubbing event with no mask wearing, no social distancing, at maximum room capacity. 1,200 healthy volunteers aged 18-49 years and fully vaccinated will be included. Participants are recruited by group of up to 10, to be randomized 2:1 to experimental group (800 volunteers in a venue ) or control group (400 volunteers asked to stay at home). All participants will provide a salivary sample the day of experiment and seven days later. Participants will also answer surveys on the social and psychological impact of lockdown and indoor club closing, attitude towards vaccination, behaviour at risk of COVID-19 transmission during the day of the event (for both groups) as well as follow-up surveys on symptoms that participant may experience. Virological analyses include polymerase chain reaction (PCR) of salivary samples and air of the venue, investigating SARS-CoV-2 PCR.


Recruitment information / eligibility

Status Completed
Enrollment 1216
Est. completion date February 26, 2022
Est. primary completion date October 17, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 49 Years
Eligibility Inclusion Criteria: - Aged between 18 and 49 years old - Vaccination completed - People who declared to have no risk factor to severe form for Covid-19 disease - People who declared not to live in the same place as someone with these risk factors - People residing in Ile-de-France area - People affiliated with the the French social security citizen scheme Exclusion criteria: - Presence of symptoms of COVID in the 2 weeks before the event - Pregnant woman or woman who declares not having an effective contraception method - Self identification of medical conditions or comorbidities identified as a proven risk of severe COVID infection - People living with a person with these risk factors - Confirmed diagnosis of SARS-CoV-2 within two weeks before the event - Participants under tutorship or curatorship; - Underage participants; - Participants unable to give free and informed consent; - Participants not affiliated to the French social security citizen scheme: obligation to join a social security scheme or be a beneficiary thereof. - Participants under legal protection

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Club event
Participate in a club event without a mask, indoors, with vaccinated people.

Locations

Country Name City State
France ANRS Paris

Sponsors (3)

Lead Sponsor Collaborator
ANRS, Emerging Infectious Diseases Cerballiance, Kappa Santé

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of positive RT-PCR at day 7 Number of participants in each groups with a positive salivary RT-PCR Day 7
Secondary Number of SARS-CoV-2 infection cases Numbers of asymptomatic, symptomatic, and severe SARS-CoV-2 infection according to a self-assessment by a questionnaire sent online in each group Day 5 up to day 10
Secondary Number of participants with seasonal respiratory viruses Number of participants in each group with a positive seasonal respiratory viruses PCR Day 0 and day 7
Secondary Number of symptomatic and asymptomatic respiratory infection Numbers of asymptomatic, symptomatic, and severe seasonal respiratory viruses infection according to a self-assessment by a questionnaire sent online Day 5 to day 10
Secondary Number of detected virus in the air Number of detected virus in the air, by the AerosolSense Day 0
Secondary Number of mutations, deletions and insertions on the viral genome in participants samples Whole genome sequencing of virus detected in participants samples : number of mutations, deletions or insertions on all the viral genes of consensus sequences Day 0 and day 7
Secondary Number of mutations, deletions and insertions on the viral genome in Aerosol samples Whole genome sequencing of virus detected in Aerosol samples : number of mutations, deletions or insertions on all the viral genes of consensus sequences Day 0 and day 7
Secondary Percentage of divergence between phylogenetic analysis of participants and aerosol samples Establishing the distance matrix between the viruses in participants samples and viruses detected by aerosol sense Day 0 and day 7
Secondary Percentage of Health protocol adherence Percentage of positive responses to a questionnaire assessing degree of adherence to the health protocol by questionnaire sent online to participants and organizers after the evenings. Day 1
Secondary Percentage of Interactions between the participants during the event Percentage of responses to a questionnaire assessing number of individual interactions during the event Day 1
See also
  Status Clinical Trial Phase
Recruiting NCT05520216 - Effect of Rib Cage and Spine Mobility on Maximum Breath-Hold Time
Active, not recruiting NCT04807465 - Different Modes of Universal Adhesive in Smokers and Non-Smokers N/A
Completed NCT06087055 - Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy Participants Phase 1
Completed NCT04962022 - Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants Phase 1
Completed NCT04962230 - Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir Phase 1
Completed NCT05450549 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants Phase 1
Active, not recruiting NCT04814836 - Laser Etching Effect on Application Mode of Universal Adhesive N/A